Paper37831007
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.
Wei D and 4 others. Clin Cancer Res, 2024. Cited by 145 papers, by iCite.
Cite this record
ConductScience Library. A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer. Papers, record 37831007. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37831007
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Pancreatic Neoplasms | Major topic |
| Carcinoma, Pancreatic Ductal | Major topic |
| Heterocyclic Compounds, 2-Ring | Major topic |
| Naphthalenes | Major topic |
| Humans | |
| Proto-Oncogene Proteins p21(ras) | |
| Mutation |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P50 CA221707 | NCI NIH HHS | United States | P50CA221707 | PubMed | NIH RePORTER |
| R01 CA236905 | NCI NIH HHS | United States | R01CA236905 | PubMed and NIH | NIH RePORTER |
| R01 CA198090 | NCI NIH HHS | United States | R01CA198090 | PubMed and NIH | NIH RePORTER |
| P30 DK056338 | NIDDK NIH HHS | United States | P30DK056338 | PubMed and NIH | NIH RePORTER |
| R01 CA220236 | NCI NIH HHS | United States | R01CA220236 | PubMed and NIH | NIH RePORTER |
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 39279937 | Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer. | https://conductscience.org/library/papers/39279937 | PubMed |
| Comment in | 39279949 | MRTX1133's promise for treating KRASG12D-mutant pancreatic cancer. | https://conductscience.org/library/papers/39279949 | PubMed |
References66
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26436951 | PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors. | Oncogenesis | 2015 | https://conductscience.org/library/papers/26436951 | PubMed |
| 2 | 27010960 | KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. | Clin Transl Gastroenterol | 2016 | https://conductscience.org/library/papers/27010960 | PubMed |
| 3 | 34518295 | Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. | Mol Cancer Ther | 2021 | https://conductscience.org/library/papers/34518295 | PubMed |
| 4 | 36618907 | Discovery of potent and noncovalent KRASG12D inhibitors: Structure-based virtual screening and biological evaluation. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36618907 | PubMed |
| 5 | 22589270 | A comprehensive survey of Ras mutations in cancer. | Cancer Res | 2012 | https://conductscience.org/library/papers/22589270 | PubMed |
| 6 | 29229669 | KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. | Cold Spring Harb Perspect Med | 2018 | https://conductscience.org/library/papers/29229669 | PubMed |
| 7 | 24256730 | K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. | Nature | 2013 | https://conductscience.org/library/papers/24256730 | PubMed |
| 8 | 32250617 | Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer. | J Med Chem | 2020 | https://conductscience.org/library/papers/32250617 | PubMed |
| 9 | 37059070 | Pancreatic cancer: Advances and challenges. | Cell | 2023 | https://conductscience.org/library/papers/37059070 | PubMed |
| 10 | 21993244 | RAS oncogenes: weaving a tumorigenic web. | Nat Rev Cancer | 2011 | https://conductscience.org/library/papers/21993244 | PubMed |
| 11 | 37277530 | An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance. | Nat Cancer | 2023 | https://conductscience.org/library/papers/37277530 | PubMed |
| 12 | 34547082 | Pancreatic Cancer: A Review. | JAMA | 2021 | https://conductscience.org/library/papers/34547082 | PubMed |
| 13 | 26091808 | A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. | Ann Oncol | 2015 | https://conductscience.org/library/papers/26091808 | PubMed |
| 14 | 35075146 | KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. | Cell Discov | 2022 | https://conductscience.org/library/papers/35075146 | PubMed |
| 15 | 32047043 | The small molecule BI-2852 induces a nonfunctional dimer of KRAS. | Proc Natl Acad Sci U S A | 2020 | https://conductscience.org/library/papers/32047043 | PubMed |
| 16 | 26037647 | Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. | Mol Cancer Res | 2015 | https://conductscience.org/library/papers/26037647 | PubMed |
| 17 | 32247999 | Immunotherapy for pancreatic cancer: A 2020 update. | Cancer Treat Rev | 2020 | https://conductscience.org/library/papers/32247999 | PubMed |
| 18 | 37068173 | Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. | Cancer Discov | 2023 | https://conductscience.org/library/papers/37068173 | PubMed |
| 19 | 32046984 | Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. | Cancer Discov | 2020 | https://conductscience.org/library/papers/32046984 | PubMed |
| 20 | 19208745 | KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin. | Mol Cancer Res | 2009 | https://conductscience.org/library/papers/19208745 | PubMed |
Cited by103
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 145 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42935756 | Metabolic sensing in 3D models of pancreatic ductal adenocarcinoma: probing pH, oxygen, and lactate dynamics to decode chemoresistance. | Front Bioeng Biotechnol | 2026 | https://conductscience.org/library/papers/42935756 | PubMed |
| 42840361 | KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42840361 | PubMed |
| 42829436 | Targeting adaptive EGFR feedback enhances the therapeutic efficacy of RMC-6236 in cholangiocarcinoma. | Exp Hematol Oncol | 2026 | https://conductscience.org/library/papers/42829436 | PubMed |
| 42794928 | Advances in KRAS-Targeted Therapies for Pancreatic Cancer. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42794928 | PubMed |
| 42712971 | RAS signaling and remodeling of the immune microenvironment in pancreatic ductal adenocarcinoma: implications of emerging RAS-targeted therapy. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42712971 | PubMed |
| 42649442 | KRAS and TP53 Circulating Tumor DNA are Prognostic in Localized Pancreatic Cancer. | Ann Surg Oncol | 2026 | https://conductscience.org/library/papers/42649442 | PubMed |
| 42645357 | Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42645357 | PubMed |
| 42629972 | Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study. | Int J Cancer | 2027 | https://conductscience.org/library/papers/42629972 | PubMed |
| 42622884 | KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms. | Med Oncol | 2026 | https://conductscience.org/library/papers/42622884 | PubMed |
| 42591541 | Bergamottin demonstrates preclinical effectiveness against pancreatic cancer by modulating PPAR-γ to induce apoptosis. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42591541 | PubMed |
| 42528591 | Research progress of small molecule targeted drugs for non-small cell lung cancer. | Front Oncol | 2026 | https://conductscience.org/library/papers/42528591 | PubMed |
| 42520352 | Rac/Cdc42 inhibitors target pancreatic cancer cells and macrophages in the tumor microenvironment. | Cancer Treat Res Commun | 2026 | https://conductscience.org/library/papers/42520352 | PubMed |
| 42513436 | Precision Therapeutics in Pancreatic Cancer: Emerging Targeted, Immune, and Antibody-Drug Conjugate Strategies Exemplified by Adagrasib, Dostarlimab, and Trastuzumab Deruxtecan. | J Clin Med | 2026 | https://conductscience.org/library/papers/42513436 | PubMed |
| 42453876 | Therapeutic inhibition of RAS in non-small cell lung cancer. | Front Oncol | 2026 | https://conductscience.org/library/papers/42453876 | PubMed |
| 42422981 | Synthetic lethality targets in pancreatic ductal adenocarcinoma: prevalence and limitations of liquid biopsy detection in a minority-serving cancer center. | Future Oncol | 2026 | https://conductscience.org/library/papers/42422981 | PubMed |
| 42393724 | KRAS inhibition is an effective therapy for appendiceal adenocarcinoma. | J Hematol Oncol | 2026 | https://conductscience.org/library/papers/42393724 | PubMed |
| 42377115 | High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42377115 | PubMed |
| 42370145 | Research progress on the etiology and pathogenesis of pancreatic cancer: a narrative review. | Front Oncol | 2026 | https://conductscience.org/library/papers/42370145 | PubMed |
| 42356482 | Dehydrocorydaline Exerts Anti-Pancreatic Cancer Effects Through the PI3K/Akt/mTOR Pathway. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42356482 | PubMed |
| 42327248 | Rosindol: A fluorogen for the quantitative measurement of reactive oxygen species in living cells. | bioRxiv | 2026 | https://conductscience.org/library/papers/42327248 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37831007
GET https://conductscience.org/api/papers/v1/37831007/references?page=2